In this article, we review the underlying biology and pharmacology behind lapatinib and summarize clinical trials with lapatinib. We also describe the ongoing clinical trials that use lapatinib as part of adjuvant and neoadjuvant therapy. These trials could change the standard of care in the next few years. More>>

Colorectal cancer (CRC) remains the second leading cause of cancer death in the United States. However, the survival for patients with metastatic CRC (mCRC) has improved dramatically over the last decade. This article will focus on the molecularly targeted agents that are being used regularly in the treatment of CRC, as well as highlight a number of new agents/targets that are being explored. More>>

Unlike stages I and II, where surgical resection represents the standard therapy, and stage IV where, with rare exceptions, surgery is not recommended, the role of surgical resection in patients with stage III NSCLC remains a subject of debate. More>>

Adjuvant therapy for resected non-small cell lung cancer (NSCLC) continues to be an evolving area. The foundation of curative treatment for early stage disease is resection for patients who are operative candidates. However, despite early detection, there continues to be a significant risk of relapse and death even with complete (R0) resection. More>>

This review focuses on discussing the efficacy and cardiotoxicity of anthracycline and trastuzumab combination regimens compared to nonanthracycline and trastuzumab regimens. More>>

We are pleased to introduce the second of four E-Updates that will be presented to you, between now and the end of the year, in a series entitled HER1 and HER2 Targeting in Breast Cancer, Volume 2. More>>

A subset of breast cancers are characterized by amplification of the HER2 oncogene and overexpression of the HER2 oncoprotein at the tumor cell surface. This distinguishing attribute has afforded unique opportunities for the development of targeted therapies for the treatment of this disease subtype. More>>

Strides made in the treatment of metastatic breast cancer (MBC) appear to prolong survival in some settings, but the cost in terms of quality of life (QOL) remains a concern. The previous four E-Updates in this series on metastatic breast cancer have focused on the various treatment options, including chemotherapy, anti-HER2 targeted therapy, antiangiogenic therapy, and hormonal therapy. In this E-Update, we turn to the role of supportive measures in the treatment of cancer,... More>>

A significant proportion of patients with non-small cell lung cancer (NSCLC) present with locally advanced, unresectable disease. For the most part, fit patients with this diagnosis are treated with combined-modality therapy. Relatively few are rendered resectable. Over the past two decades, combination chemotherapy and radiation, preferably concurrent chemoradiation, has emerged as the standard of care. However, survival gains have been offset, to some extent, by local, normal-tissue, in-field... More>>

In this latest installment in the E-Updates series of educational programs, Dr. Hyman Muss, of the University of Vermont College of Medicine and the Vermont Cancer Center, presents eight important abstracts on optimizing the use of tamoxifen and aromatase inhibitors in early breast cancer that were presented at three recent major breast cancer meetings. More>>